Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results

In recent news, Merck’s MK-2214, a novel antibody targeting phosphorylated serine 413 (pS413), has earned FDA fast-track designation following …